Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.66 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679786 | 0.98 | LTA4H (0.68) | LTA4HGABRR1CYP1A2ACE2BLM | |
| SCHEMBL9001608 | 0.86 | ACE2 (0.64) | LTA4HGABRR1CYP1A2ACE2BLM | |
| SCHEMBL20612872 | 0.86 | ACE2 (0.64) | LTA4HGABRR1CYP1A2ACE2BLM | |
| SCHEMBL31073666 | 0.86 | ACE2 (0.64) | LTA4HGABRR1CYP1A2ACE2BLM | |
| SCHEMBL5977939 | 0.86 | ACE2 (0.64) | LTA4HGABRR1CYP1A2ACE2BLM | |
| SCHEMBL1193585 | 0.86 | LTA4H (0.59) | LTA4HGABRR1CYP1A2ACE2BLM | |
| SCHEMBL3811423 | 0.84 | CYP1A2 (0.67) | LTA4HCYP1A2ACE2BLMALOX15 | |
| SCHEMBL22190484 | 0.84 | LTA4H (0.62) | LTA4HGABRR1CYP1A2ACE2BLM | |
| SCHEMBL2835395 | 0.84 | CYP1A2 (0.67) | LTA4HCYP1A2ACE2BLMALOX15 | |
| SCHEMBL21998 | 0.84 | CYP1A2 (0.67) | LTA4HCYP1A2ACE2BLMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408279-A1 | SUPRAMOLECULAR-COVALENT COMPOSITE SLURRY FOR CARTILAGE REPAIR | NORTHWESTERN UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| WO-2023056433-A1 | SUPRAMOLECULAR-COVALENT COMPOSITE SLURRY FOR CARTILAGE REPAIR | NORTHWESTERN UNIVERSITY (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20180263751-A1 | POST-SURGICAL HEALING ACCELERATOR | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2018-09-20 | — | — | US | disclosed |
| EP-1622569-A4 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | INCYTE CORP (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1622569-A2 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Corporation (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1536838-A1 | CONJUGATED HYDROXYALKYL STARCH ALLERGEN COMPOUNDS | Fresenius Kabi Deutschland GmbH (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004096139-A2 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1448607-A1 | COMPOSITION AND METHOD TO HOMOGENEOUSLY MODIFY OR CROSS-LINK CHITOSAN UNDER NEUTRAL CONDITIONS | Biosyntech Canada Inc. (CA) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004030701-A1 | CONJUGATED HYDROXYALKYL STARCH ALLERGEN COMPOUNDS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003042250-A1 | COMPOSITION AND METHOD TO HOMOGENEOUSLY MODIFY OR CROSS-LINK CHITOSAN UNDER NEUTRAL CONDITIONS | BIOSYNTECH CANADA INC. (CA) | 2003-05-22 | — | — | WO | disclosed |
| EP-0658203-A1 | MODIFIED FUNGAL CELLS AND METHOD FOR PRODUCING RECOMBINANT PRODUCTS | Aventis Pharma S.A. (FR) | 1995-06-21 | — | — | EP | disclosed |
| WO-1994004687-A1 | MODIFIED FUNGAL CELLS AND METHOD FOR PRODUCING RECOMBINANT PRODUCTS | RHONE-POULENC RORER S.A. (FR) | 1994-03-03 | — | — | WO | disclosed |